Ministry of Finance of Thailand: It is estimated that the global minimum corporate tax of 15% will be implemented from January 2025.Zhendong Pharmaceutical has set up a new health management service company. The enterprise search APP shows that recently, Shanxi Zhendong Health Management Service Co., Ltd. was established, with Zhao Jin as the legal representative and a registered capital of 10 million yuan. Its business scope includes: remote health management services; Health consulting services (excluding medical services), etc. Enterprise investigation shows that the company is wholly owned by Zhendong Pharmaceutical.Musk: Grok can now generate four images at the same time and render them step by step.
The turnover of Shanghai and Shenzhen stock markets exceeded 1 trillion yuan for the 53rd consecutive trading day.From January to October, the total output of lithium batteries in China increased by 16% year-on-year. According to the Ministry of Industry and Information Technology, China's lithium-ion battery industry continued to grow from January to October 2024. According to the announcement of lithium battery industry norms, enterprise information and industry associations, the total output of lithium batteries in China from January to October was 890GWh, up 16% year-on-year. According to the data of the National Bureau of Statistics, the profit of China's lithium battery manufacturing industry increased by 39.4% from January to October. In the battery sector, the output of energy storage lithium batteries exceeded 200GWh from January to October. The loading capacity of power lithium batteries for new energy vehicles is about 405GWh. From January to October, the total export of lithium batteries in China reached 350.2 billion yuan, down 9.2% year-on-year, and the decline was 3.3 percentage points narrower than that in January-June.Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.
Huaan, AVIC, etc. lined up to enter the ranks of public offering warehousing logistics REITs. According to the announcement of AVIC Fund, the AVIC Yishang warehousing logistics REITs jointly built with ESR Group, the largest new economic real estate management company in the Asia-Pacific region, are being issued. This is the first REIT issued by ESR Group in China, and its infrastructure assets consist of three warehousing and logistics parks, namely, Phase I, Phase II and Phase III of Fulaide Kunshan Logistics Park. According to the data of wind, up to now, Huaxia Fund, harvest fund, Huatai Securities Asset Management, Hongtu Innovation Fund and CICC Fund all have a listed warehousing and logistics REIT, while Huaan Waigaoqiao REIT, which was established on December 12th, has not been listed yet. In addition, Huaxia Fund and southern fund's newly declared warehousing logistics REIT are in the inquiry stage, while Huitianfu's warehousing logistics REIT is in the feedback stage.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide 12-13